Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zigakibart - Chinook Therapeutics

Next Previous
X
Search
Drug Profile

Zigakibart - Chinook Therapeutics

Alternative Names: Anti-APRIL monoclonal antibody - Chinook Therapeutics; BION-1301; FUB 523; FUB-523 - Novartis

Latest Information Update: 06 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aduro BioTech
  • Developer Aduro BioTech; Chinook Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III IgA nephropathy
  • Discontinued Multiple myeloma

Most Recent Events

  • 06 Feb 2024 Novartis plans to file a regulatory submissions for zigakibart for IgA nephropathy in or after 2027 (Novartis pipeline, February 2024)
  • 05 Jan 2024 SanReno Therapeutics has been acquired by Novartis
  • 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top